Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n = 9963) or allogeneic (n = 3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/ MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P o 0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P = 0.04) or secondary malignancies (P o0.001) and receiving cord blood stem cell (P = 0.03) or involved field radiotherapy (P = 0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.
INTRODUCTION
High-dose therapy with autologous hematopoietic cell transplantation (HCT) can result in long-term, disease-free and overall survival in patients with relapsed lymphoma. With longer follow-up, lymphoma patients have significant risk of therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) following autologous HCT. [1] [2] [3] [4] The current standard protocols for autologous HCT include drugs that are known to be leukemogenic. 5 In particular, alkylating agents and topoisomerase-II inhibitors are associated with an increased risk for the development of t-AML/MDS. 5, 6 The increased use of allogeneic HCT with reduced-intensity conditioning (RIC) regimens could improve outcomes for lymphoma patients who received higher dose of chemotherapy because of the lower toxicity of RIC regimens compared to standard myeloablative conditioning regimens.
To evaluate the potential clinical approaches of allogeneic HCT with RIC in relapsed lymphoma patients, we analyzed the incidence and risk factors for the development of t-AML/MDS among lymphoma patients treated with autologous or allogeneic HCT from the Transplant Registry Unified Management Program (TRUMP) database 7, 8 collected and sponsored by the Japanese Society for Hematopoietic Cell Transplantation (JSHCT) and Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT).
database are performed with an informed consent. The data management committee of the JSHCT and the Institutional Review Board of Kyushu Medical Center approved this study.
Patient selection
Review of the TRUMP database identified 15 502 patients aged 415 years who underwent one or two autologous, one autologous and one allogeneic, or one allogeneic HCT for lymphoma between January 1985 and December 2012. Patients with a history of solid cancers before HCT (n = 183) were excluded. Of the 15 319 patients, 13 810 (90.1%) had sufficient follow-up data and were included in this analysis. Baseline patient variables included age at HCT and diagnosis; sex; Eastern Cooperative Oncology Group (ECOG) performance status (PS) at HCT and diagnosis; World Health Organization classification at diagnosis; disease risk (low; indolent B-cell lymphoma: intermediate; Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), transformed indolent B-non-Hodgkin lymphoma, mantle cell lymphoma, nodal T-cell lymphoma: High, extranodal T-cell lymphoma), 9 Ann Arbor stage at diagnosis; international prognostic index (IPI) at diagnosis; number of nodes at diagnosis; lactate dehydrogenase (LDH) elevation at diagnosis; the number of regimens before HCT; the number of HCT; time from diagnosis to HCT; disease status and stage risk at HCT (low; first complete remission (CR), second or subsequent CR, first partial remission (PR), untreated: High, second or subsequent PR, active relapse), 9 year at HCT; infection at HCT; HCT-specific comorbidity index (HCT-CI); and stem cell source. Patient variables assessed before and after HCT included conditioning regimens; time of granulocyte colony-stimulating factor (G-CSF) to promote engraftment and neutrophil engraftment; the occurrence of secondary graft failure and malignancies, and t-AML/MDS, onset time (time between HCT and the occurrence of t-AML/MDS) and origin of t-AML/MDS, relapse or refractory after HCT, survival rate, overall survival (OS), and cause of death were calculated. Neutrophil engraftment was defined as time to absolute neutrophil count of 4500 neutrophils/QUOTE L sustained for 3 consecutive days. The data from patients who received one HCT were censored at the date of the last reported follow-up. The data from patients who received second HCT were censored at the day of second HCT. Outcomes analyzed included OS.
Additional data collection and cytogenetic features of t-AML/MDS
We conducted an additional data collection to obtain important information on the patients with t-AML/MDS, such as cytogenetic features and the availability of allogeneic HCT for t-AML/MDS. Cytogenetic features, treatment modality applied for t-AML/MDS, result of the anti-leukemic treatment and the clinical outcome were documented if available. The median time interval between the last reported follow-up and the additional data collection for patients with t-AML/MDS was used.
Statistical methods
The frequencies and descriptive statistics of the patient-, disease-, and transplantation-related variables from groups of patients receiving autologous (including first or second autologous) and allogeneic (including first allogeneic or first autologous and second allogeneic) HCT were determined. Categorical variables in the two groups were compared using the Pearson`s chi-square test or Fisher's exact test when appropriate, and continuous variables were compared using the Mann-Whitney U-test. To accommodate competing risks, such as death and sequential HCT for relapsed lymphoma, cumulative incidence for t-AML/MDS was estimated, and differences were compared using Gray's test. The 95% confidence intervals (CIs) for all probabilities and P values of pairwise comparisons were derived from point-wise estimates and calculated.
Patient-related variables included age at HCT or diagnosis, sex, PS at HCT or diagnosis, the number of regimens before HCT, the number of HCT, time from diagnosis to HCT, year at HCT, infection at HCT, and HCT-CI at HCT. Disease-related variables included disease risk, stage risk at HCT, and Ann Arbor stage, IPI, number of lymph nodes, and LDH elevation. Transplantation-related variables included drug used for conditioning regimens, cord blood stem cell (CBSC) as graft type, time of G-CSF to Abbreviations: BM = bone marrow; CBSC = cord blood stem cell; CR1 = first complete remission; DLBCL = diffuse large B cell lymphoma; ECOG = eastern cooperative oncology group; FL = follicular lymphoma; HCT = hematopoietic cell transplantation; HCI-CI = HCT-specific comorbidity index; HL = Hodgkin lymphoma; IPI = international prognostic index; LDH = lactate dehydrogenase; M = month; N = total number of patients assessments; NK-T = natural killer T-cell lymphoma; PS = performance status; PTCL-NOS = peripheral T-cell lymphoma-not otherwise specified; PBSC = peripheral blood stem cell. Impact of HCT on the risk of t-AML/MDS in lymphoma patients S Yamasaki et al promote engraftment, time of neutrophil engraftment, secondary graft failure, secondary malignancies (secondary cancers except for t-AML/MDS after HCT), t-AML/MDS, onset time of t-AML/MDS after last HCT, year of allogeneic HCT, and relapse or refractory after HCT. OS was calculated using the Kaplan-Meier method, and two-group comparisons were performed using the log-rank test and multivariate Cox regression analyses. The Cox proportional hazard model included patient-, disease-, and transplantation-related variables. The dependent variable was time to any t-AML/MDS; a sensitivity analysis was performed on time to t-AML/MDS as the first event. The stepwise method consisted of including or removing one independent variable at each step. Two-sided P values o0.05 were considered statistically significant. All statistical analyses were performed using the statistical package Stata Version 13 (Stata Corporation, College Station, Texas, USA) or EZR (Saitama Medical Center, at http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0). EZR is a modified version of R commander (version 1.6-3) designed to add statistical functions that are frequently used in biostatistics. 10 Table 1 shows the patient-, disease-, and transplantation-related variables in the two groups of lymphoma patients. The 13 810 patients with lymphoma were divided into two groups: those receiving autologous HCT (n = 9963) or allogeneic HCT (n = 3847). Patient age at HCT and diagnosis, the number of patients with DLBCL and the number of patients with first complete remission (CR1) at HCT were higher in the autologous HCT group. The percentages of ECOG PS at HCT, disease risk, Ann Arbor stage, the number of nodes, LDH elevation, the number of regimens before HCT, the number of HCT, longer time from diagnosis, higher stage risk at HCT, the percentages undergoing HCT after 2006, infection at HCT, as well as higher HCT-CI were higher in patients receiving allogeneic HCT compared with those receiving autologous HCT. There were no statistically significant differences in sex, ECOG PS at diagnosis and IPI between patients receiving autologous HCT and those receiving allogeneic HCT.
RESULTS

Patient characteristics
HCT outcomes Table 2 shows the patient characteristics and outcomes of HCT in the two groups of lymphoma patients receiving autologous HCT, including first (n = 9566) or second (n = 397) autologous HCT and allogeneic HCT, including first allogeneic (n = 2723) or first autologous and second allogeneic (n = 1124) HCT. With regard to HCT conditioning, the percentages of patients receiving conditioning with cyclophosphamide, cytarabine, etoposide, and rituximab were higher in patients receiving autologous HCT ( Table 2 ). The percentages of patients receiving conditioning with total body irradiation, fludarabine, oral and intravenous busulfan were higher in patients receiving allogeneic HCT. With regard to HCT outcomes, a longer duration of G-CSF, later neutrophil engraftment, and higher number of secondary graft failures was observed in patients receiving allogeneic HCT. Regarding t-AML/MDS, a higher number of patients with t-AML/MDS and longer onset of t-AML/MDS was observed in patients receiving autologous HCT. There were no statistically significant differences in the percentage of patients receiving conditioning with melphalan and involved-field radiotherapy (IFRT) and the number of patients with secondary malignancies, between patients receiving autologous HCT and those receiving allogeneic HCT. Median follow-up times for survivors receiving Abbreviations: G-CSF = granulocyte colony-stimulating factor; GVHD = graft versus host disease; HCT = hematopoietic cell transplantation; IFRT = involved field radiotherapy; M = month; N = total number of patients assessments; NE = not examined; TBI = total body irradiation; t-AML/MDS = therapy-related acute myeloid leukemia and myelodysplastic syndrome. Impact of HCT on the risk of t-AML/MDS in lymphoma patients S Yamasaki et al autologous HCT or those receiving allogeneic HCT were 52 and 46 months, respectively.
Impact of factors on the risk of t-AML/MDS Lymphoma patients who underwent autologous HCT (one or two autologous HCT; 0.22, 0.83 and 1.38%; 95% CI 0.01%-0.30%, 0.06%-1.05% and 1.09%-1.68%, at 1, 2 and 3 years after autologous HCT, respectively) had a significant risk of developing t-AML/MDS compared to allogeneic HCT (one autologous and one allogeneic or one allogeneic HCT; 0.04, 0.28 and 0.37%; 95% CI 0.01%-0.11%, 0.03%-0.44% and 0.06%-0.67%, at 1, 2 and 3 years after allogeneic HCT, respectively; Figure 1a ). Lymphoma patients who underwent one autologous HCT (0.23%, 0.81 and 1.36%; 95% CI 0.12%-0.33%, 0.59%-1.03% and 1.06%-1.66%, at 1, 2 and 3 years after autologous HCT, respectively) had a significant risk of developing t-AML/MDS compared to one allogeneic HCT (0.08, 0.37 and 0.55%; 95% CI 0.01%-0.25%, 0.04%-0.74% and 0.04%-1.05%, at 1, 2 and 3 years after allogeneic HCT, respectively; Figure 1b ). The higher risk of developing t-AML/MDS after autologous HCT compared to allogeneic HCT was similar among DLBCL (Supplementary Figure S1) , Hodgkin lymphoma (HL, Supplementary Figure S2 ), follicular lymphoma (FL, Supplementary Figure S3) , peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS, Supplementary Figure S4 ) and natural killer T-cell lymphoma patients (NK-T, data not shown). There were no statistical differences in the cumulative incidence of developing t-AML/MDS among patients with DLBCL, HL, FL, PTCL-NOS and NK-T who underwent autologous HCT (P = 0.52). After allogeneic HCT, t-AML/MDS occurred in patients with DLBCL (n = 8), FL (n = 1) and angioimmunoblastic T-cell lymphoma (n = 1). Multivariate Cox regression analysis (Table 3) showed that stage risk at HCT (P = 0.04) and secondary malignancies (P o 0.001) were independent risk factors of t-AML/MDS in patients receiving autologous HCT. Regarding those receiving allogeneic HCT, CBSC (P = 0.03) and IFRT (P = 0.002) were independent risk factors of t-AML/MDS. There were no significant differences in OS after t-AML/MDS diagnosis between patients receiving allogeneic HCT (n = 10) and those receiving autologous HCT (n = 211, log-rank, P = 0.34). There were no significant differences in OS after t-AML/MDS diagnosis between patients receiving one allogeneic HCT (n = 7) and those receiving one autologous HCT (n = 205, log-rank, P = 0.26). Additionally, t-AML/MDS was a risk factor for OS after t-AML/MDS diagnosis in patients surviving 100 days after autologous or allogeneic HCT (log-rank, P o0.001; Supplementary  Figures 5,6 ). OS after t-AML/MDS diagnosis in patients receiving allogeneic HCT tended to be worse than that in patients receiving autologous HCT (log-rank, P = 0.068; Supplementary Figure 7) .
Impact of cytogenetic features and availability of allogeneic HCT for t-AML/MDS Additional data collection from 46 transplant centers was available for 62 of 220 patients with t-AML/MDS: 56/211 (26.5%) in t-AML/MDS patients receiving autologous HCT and 6/10 (60%) in those receiving allogeneic HCT (Table 4) . Data on cytogenetic evaluation were available for 62 patients: 41/56 patients (73%) receiving autologous HCT and 6/6 patients (100%) receiving allogeneic HCT had cytogenetic abnormalities; abnormalities in chromosome 5 and/or chromosome 7 were found in 28/56 (50%) after autologous HCT and 5/6 (83%) after allogeneic HCT; balanced translocations, such as mixed-lineage leukemia rearrangement 11q23 and t(15;17), were detected in 4/56 (7%) after autologous HCT and 0/6 after allogeneic HCT; complex karyotypes were observed in 17/56 (30%) after autologous HCT and 4/6 (67%) after allogeneic HCT.
Allogeneic HCT for t-AML/MDS was available for 20/62 patients (32%): 18/56 (32%) after autologous HCT and 2/6 (33%) after allogeneic HCT. Among 56 patients in the autologous HCT group, t-AML/MDS patients who underwent allogeneic HCT, compared with those who did not undergo allogeneic HCT, had a significantly better OS from onset of t-AML/MDS (median OS 72 vs 60 months, P = 0.043), whereas the number of patients with high disease risk was significantly higher among those who did not undergo allogeneic HCT. Among 6 patients in the allogeneic HCT group, all patients died: 2/2 patients who underwent allogeneic HCT died as a result of transplant-related toxicities and 4/4 patients who did not undergo allogeneic HCT died as a result of t-AML/MDS in the CR state of lymphoma after the primary allogeneic HCT.
The number of patients with Ann Arbor stage 4 and the percentages of patients receiving conditioning with etoposide were significantly higher in the autologous HCT group compared with the group of patients with t-AML/MDS after autologous and allogeneic HCT. The number of HCT, the percentages of patients receiving conditioning with TBI and Flu, the longer duration of G-CSF, the later neutrophil engraftment and higher scores of revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes (MDS) were significantly higher in the allogeneic HCT group.
DISCUSSION
To the best of our knowledge, this is the largest analysis of the incidence and risk factors for the development of t-AML/MDS Impact of HCT on the risk of t-AML/MDS in lymphoma patients S Yamasaki et al among lymphoma patients receiving autologous HCT. It is also the first study on t-AML/MDS among lymphoma patients receiving allogeneic HCT. The major findings were as follows: t-AML/MDS among lymphoma patients receiving autologous HCT and/or allogeneic HCT was a rare event; the risk of developing t-AML/ MDS was high-stage risk at HCT and secondary malignancies in the autologous group, and CBSC and IFRT in the allogeneic HCT group; t-AML/MDS mostly presented with unfavorable cytogenetic features; and although the overall outcome of t-AML/MDS was still poor, patients proceeding to allogeneic HCT had a significantly improved outcome after autologous HCT, not allogeneic HCT. The risks of developing t-AML/MDS after autologous HCT have been reported previously. 5 Our study showed the risk of t-AML/MDS after autologous HCT was associated with high-stage risk at HCT and secondary malignancies. These observations indicate that autologous HCT should not be selected for patients with high-stage risk at HCT because high-dose chemotherapy with autologous HCT has not been able to overcome drug resistance of all lymphomas. In the current study, secondary malignancies were detected for the highest risk of developing t-AML/MDS after autologous HCT. This suggests that chemotherapies for lymphoma lead to genotoxic damage, which then causes abnormal hematopoietic or cell clones associated with t-AML/MDS or secondary malignancies, respectively. Of note, CBSC and IFRT increase the risk of t-AML/MDS in those receiving allogeneic HCT. Several studies have identified delayed neutrophil or platelet engraftment following autologous HCT was a risk factor for t-AML/MDS. 11, 12 The recovery of peripheral blood cell counts and marrow cellularity may be an insensitive measure of hematopoietic reconstitution and high proliferative stress during engraftment, which could amplify abnormal clones bearing genotoxic damage from pre-HCT therapies and conditionings for HCT. In support of this, several studies have identified a decreased dose of infused graft as a risk factor for t-AML/MDS, which could occur in allogeneic HCT with CBSC or IFRT.
Among t-AML/MDS patients with known genetic characteristics in this analysis, alterations of chromosome 5 and/or 7 were most commonly observed and complex karyotypes were documented.
The risk of t-AML/MDS was significant increased 5 to 8 years after exposure to alkylating agents; in contrast, etoposide and other topoisomerase-II inhibitors typically induce t-AML/MDS with a short latency period of about 2 years after exposure. 5 In addition to the latency periods, t-AML/MDS can often be attributed to either alkylating agents or topoisomerase-II inhibitors on the basis of characteristic genetic alterations. Alkylating agents typically induce alterations of chromosome 5 and/or 7, and t-AML/MDS after exposure to topoisomerase-II inhibitors is associated with a rearrangement of the MLL gene and/or balanced chromosomal translocations, including t(15;17). [13] [14] [15] Our findings are consistent with a recent analysis of patients diagnosed with t-AML/MDS after different lymphomas, which reported a significantly increased proportion of patients with unfavorable genetic alterations compared with de novo AML. 16 Balanced translocations were detected only in patients after autologous HCT, not allogeneic HCT. This may be associated with the number of patients treated with etoposide because balanced translocations appear to correlate with the usage of topoisomerase-II inhibitors, such as etoposide. 13 Our study revealed an increased risk of developing t-AML/MDS for patients treated with one autologous and one allogeneic HCT compared to patients treated with one allogeneic HCT. This finding is not unexpected because the cumulative doses of leukemogenic drugs appear to correlate with the risk of developing t-AML/MDS. As shown in an analysis from Stanford University reporting the incidence and outcome of t-AML/MDS among HL patients, a reduction in the cumulative doses of alkylating agents resulted in a significant decrease of the t-AML/MDS rate. 17 The reduced number of regimens and doses over the previous decades might have also had an impact on the lower t-AML/MDS incidence among patients treated for lymphoma after autologous and allogeneic HCT. A previous analysis reported 4 or more cycles of chemotherapy had a significantly higher risk for developing t-AML/MDS in HL patients when compared with patients who had received less than 4 cycles of chemotherapy. 18 Another report evaluating the role of the number cycles of chemotherapy revealed a significantly increased Abbreviations: CBSC = cord blood stem cell; CI = confidence interval; HCT = hematopoietic cell transplantation; HR = hazard ratio; HCI-CI = HCT-specific comorbidity index; IFRT = involved field radiotherapy; TBI = total body irradiation. Bold values indicate statistically significant Po 0.05.
Impact of HCT on the risk of t-AML/MDS in lymphoma patients S Yamasaki et al Table 4 . Impact of HCT on the risk of t-AML/MDS in lymphoma patients S Yamasaki et al t-AML/MDS risk for lymphoma patients who had 4 or more regimens and 8 or more cycles of chemotherapy in case series.
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Although t-AML/MDS was previously reported to have a very poor prognosis, allogeneic HCT with RIC is one of the most promising options for t-AML/MDS in lymphoma patients. 18 Selected lymphoma patients after autologous HCT, but not allogeneic HCT, were rescued by allogeneic HCT in our study. Proceeding to allogeneic HCT correlated with a better outcome in the previous reports described above. The largest study of allogeneic transplantation for t-AML/MDS was performed in Canada, but the outcome of patients undergoing allogeneic HCT for t-AML/MDS after different solid tumors and hematological malignancies, not only lymphoma, was analyzed. 20 Finke et al. reported that patients with t-AML/MDS had poor OS similar to our study, in addition unrelated donor was a significant risk factor for both higher TRM and decreased OS, and cytogenetics were predictive for OS. 21 There were some limitations in this retrospective cohort study. The effect of chemotherapies before HCT on the occurrence of t-AML/MDS was not clear because the details of treatment before HCT were not available. Even if information regarding those who developed t-AML/MDS after HCT based on TRUMP database was available, the details of treatment before HCT could not be collected by additional data collection. In addition, it is never clear what were the decision rules to go for autologous or allogeneic HCT resulting in bias; this is for example exemplified in the younger age and poor risk disease characteristics in the allogeneic group. Moreover, the patients dying from transplantation-related complications after allogeneic HCT were not included and therefore had no risk of second malignancies. Finally, it might be important to know why patients underwent allogeneic HCT for t-AML/MDS. However, it is unlikely that a retrospective cohort study would have accurate information on why patients did not receive allogeneic HCT for t-AML/MDS.
In conclusion, t-AML/MDS is rare, but lymphoma patients with t-AML/MDS after HCT are associated with a very poor prognosis. Thus, novel treatment strategies for lymphoma should aim to reduce chemotherapy and the number of HCT to reduce the risk of developing t-AML/MDS. Several trials evaluating such a treatment reduction on the basis of interim positron emission tomography have been initiated, and results from some of these studies recently became available. 22, 23 In addition, strategies to select lymphoma patients for autologous HCT more carefully, and to exclude lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at high risk for t-AML/MDS. Allogeneic HCT might be an alternative to autologous HCT in lymphoma patients at high risk for t-AML/MDS. Finally, the further optimization of allogeneic HCT might increase cure rates among lymphoma patients diagnosed with t-AML/MDS after autologous HCT.
